Retirement Planning Co of New England Inc. Sells 1,016 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Retirement Planning Co of New England Inc. reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.5% during the 4th quarter, HoldingsChannel reports. The fund owned 21,427 shares of the specialty pharmaceutical company’s stock after selling 1,016 shares during the period. Retirement Planning Co of New England Inc.’s holdings in Supernus Pharmaceuticals were worth $775,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 870 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $72,000. Venturi Wealth Management LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $92,000. KBC Group NV increased its stake in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 929 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $211,000.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

SUPN opened at $32.16 on Tuesday. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of 30.06 and a beta of 0.83. The stock’s 50 day moving average price is $36.13 and its 200-day moving average price is $35.15. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.